Capricor Therapeutics (CAPR) Gains from Investment Securities (2012 - 2026)
Capricor Therapeutics (CAPR) recorded quarterly Gains from Investment Securities of $6591.0 in Q1 2026, up 104.37% quarter-over-quarter from -$150673.0 in Q1 2025, and up 104.37% on a YoY basis from $3225.0 in Q1 2025.
Capricor Therapeutics (CAPR) Gains from Investment Securities (2012 - 2026) Analysis & Trends
Capricor Therapeutics' Gains from Investment Securities history runs 11 years deep, the most recent figure standing at $6591.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 104.37% year-over-year to $6591.0; the TTM figure through Mar 2026 stood at -$449583.0 (down 208.44% YoY), while the FY2025 annual figure was $13.4 million, changed N/A from the prior year.
- Gains from Investment Securities was $6591.0 for Q1 2026 at Capricor Therapeutics, up from -$150673.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $2.7 million in Q2 2024 to a low of -$305501.0 in Q4 2024.
- Historically, Gains from Investment Securities has averaged $1.1 million across 5 years, with a median of $867854.0 in 2022.
- The sharpest annual moves came in 2024 and 2026: Gains from Investment Securities sank 10645.43% in 2024, then jumped 104.37% in 2026.
- A 5-year view of Gains from Investment Securities shows it stood at $867854.0 in 2022, then sank by 99.67% to $2897.0 in 2023, then tumbled by 10645.43% to -$305501.0 in 2024, then soared by 50.68% to -$150673.0 in 2025, then surged by 104.37% to $6591.0 in 2026.
- The last three Gains from Investment Securities figures came in at $6591.0 (Q1 2026), -$150673.0 (Q1 2025), and -$305501.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Capricor Therapeutics | 1.53 Bn | 1.26 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,591.00 |
| Mar 31, 2026 | 6,591.00 |
| Mar 31, 2025 | -150,673.00 |
| Mar 31, 2025 | -150,673.00 |
| Dec 31, 2024 | -305,501.00 |
| Dec 31, 2024 | -305,501.00 |
| Sep 30, 2024 | 458,869.00 |
| Sep 30, 2024 | 458,869.00 |
| Jun 30, 2024 | 2.67 Mn |
| Jun 30, 2024 | 2.67 Mn |
| Mar 31, 2024 | 377,866.00 |
| Mar 31, 2024 | 377,866.00 |
| Dec 31, 2023 | 2,897.00 |
| Dec 31, 2023 | 2,897.00 |
| Sep 30, 2023 | 1.26 Mn |
| Sep 30, 2023 | 1.26 Mn |
| Jun 30, 2023 | 1.82 Mn |
| Jun 30, 2023 | 1.82 Mn |
| Mar 31, 2023 | 1.76 Mn |
| Mar 31, 2023 | 1.76 Mn |